Immune Checkpoints of the B7 Family. Part 1. General Characteristics and First Representatives: B7-1, B7-2, B7-H1, B7-H2, and B7-DC


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

T-cell response along with humoral response compose the basis of acquired immunity. Effective activation of T lymphocytes requires at least two signals. The first signal is provided by the interaction of T-cell receptor with antigenic peptide in the context of major histocompatibility complex molecules (I or II class). The second signal required for T cell activation, proliferation and differentiation is delivered by molecules called “immune checkpoints” which determine the polarity, effectiveness and termination of the immune response. The immune checkpoint group consist of around 70 members. The first discovered molecules that control immune response belong to the B7 family of cell membrane proteins. The classical two-signal model for T cell activation was developed with their implication. Immune checkpoints have gained popularity after successful clinical trials of antibodies blocking CTLA-4 and PD-1 receptors (immune checkpoint inhibitors), in which the tremendous antitumor effects were demonstrated. Considering the importance of the immune checkpoints in therapeutic regulation of antitumor immunity, in this review we describe the functional properties of all known today molecules of the B7 family. The first part of our review discusses the structural features, functions and therapeutic applications of B7-1, B7-2, B7-H1, B7-H2, B7-DC, and their receptors.

About the authors

A. I. Chapoval

Russian-American Anticancer Center, Altai State University; The Biodesign Institute, Center for Innovations in Medicine, Arizona State University

Author for correspondence.
Email: andreichapoval@gmail.com
Russian Federation, Barnaul, 656049; Tempe, AZ 85281

S. P. Chapoval

Department of Microbiology and Immunology, Center for Vascular and Inflammatory Diseases, Program in Oncology at the Greenbaum Cancer Center, University of Maryland School of Medicine

Email: andreichapoval@gmail.com
United States, Baltimore, MD, 21201

N. S. Shcherbakova

Russian-American Anticancer Center, Altai State University; FSRI SRC VB Vector, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Email: andreichapoval@gmail.com
Russian Federation, Barnaul, 656049; Koltsovo, Novosibirsk oblast, 630559

D. N. Shcherbakov

Russian-American Anticancer Center, Altai State University; FSRI SRC VB Vector, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Email: andreichapoval@gmail.com
Russian Federation, Barnaul, 656049; Koltsovo, Novosibirsk oblast, 630559

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Pleiades Publishing, Ltd.